Ascentage Pharma Group International Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Ascentage Pharma Group International şirketinin toplam hissedar öz sermayesi CN¥776.4M ve toplam borcu CN¥1.7B olup, bu da borç-öz sermaye oranını 216.3% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥3.1B ve CN¥2.3B dir.

Anahtar bilgiler

216.3%

Borç/özkaynak oranı

CN¥1.68b

Borç

Faiz karşılama oranı	n/a
Nakit	CN¥1.10b
Eşitlik	CN¥776.44m
Toplam yükümlülükler	CN¥2.33b
Toplam varlıklar	CN¥3.11b

Son finansal sağlık güncellemeleri

Ascentage Pharma Group International (HKG:6855) Has Debt But No Earnings; Should You Worry?

Dec 04

Is Ascentage Pharma Group International (HKG:6855) A Risky Investment?

Aug 30

Recent updates

What Ascentage Pharma Group International's (HKG:6855) P/S Is Not Telling You

Dec 23

Ascentage Pharma Group International's (HKG:6855) Shares Climb 26% But Its Business Is Yet to Catch Up

Sep 04

Here's Why Ascentage Pharma Group International (HKG:6855) Can Afford Some Debt

Aug 26

Ascentage Pharma Group International's (HKG:6855) Shares Climb 29% But Its Business Is Yet to Catch Up

Jun 18

Here's Why Ascentage Pharma Group International's (HKG:6855) CEO May Not Expect A Pay Rise This Year

May 03

Why We're Not Concerned Yet About Ascentage Pharma Group International's (HKG:6855) 30% Share Price Plunge

Mar 30

Are Investors Undervaluing Ascentage Pharma Group International (HKG:6855) By 40%?

Feb 17

There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price

Dec 20

Ascentage Pharma Group International (HKG:6855) Is Making Moderate Use Of Debt

Oct 28

Some Analysts Just Cut Their Ascentage Pharma Group International (HKG:6855) Estimates

Aug 27

There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price

Aug 23

Ascentage Pharma Group International (HKG:6855) Is Carrying A Fair Bit Of Debt

Jun 19

Ascentage Pharma Group International (HKG:6855) Has Debt But No Earnings; Should You Worry?

Dec 04

Is Ascentage Pharma Group International (HKG:6855) A Risky Investment?

Aug 30

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 6855 'nin kısa vadeli varlıkları ( CN¥2.0B ) kısa vadeli yükümlülüklerini ( CN¥1.1B ) aşıyor.

Uzun Vadeli Yükümlülükler: 6855 şirketinin kısa vadeli varlıkları ( CN¥2.0B ) uzun vadeli yükümlülüklerini ( CN¥1.3B ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 6855 'nin net borç/öz sermaye oranı ( 74.6% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: 6855 şirketinin 5 yıl önce negatif özkaynağı vardı, ancak şu anda pozitif ve dolayısıyla iyileşme kaydetti.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 6855 şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: 6855 tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/31 09:42
Gün Sonu Hisse Fiyatı	2024/12/31 00:00
Kazançlar	2024/06/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Ascentage Pharma Group International 13 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Yang Huang	BofA Global Research
Jin Zhang	China International Capital Corporation Limited
Wangbin Zhou	China International Capital Corporation Limited

Ascentage Pharma Group International Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Here's Why Ascentage Pharma Group International (HKG:6855) Can Afford Some Debt

Ascentage Pharma Group International (HKG:6855) Is Making Moderate Use Of Debt

Ascentage Pharma Group International (HKG:6855) Is Carrying A Fair Bit Of Debt

Ascentage Pharma Group International (HKG:6855) Has Debt But No Earnings; Should You Worry?

Is Ascentage Pharma Group International (HKG:6855) A Risky Investment?

Recent updates

Ascentage Pharma Group International has filed a Follow-on Equity Offering in the amount of $100 million.

What Ascentage Pharma Group International's (HKG:6855) P/S Is Not Telling You

Ascentage Pharma Releases the Safety and Efficacy Data of the Novel Drug Candidate, Olverembatinib (HQP1351) in Combination the Company's Investigational Novel Bcl-2 Inhibitor, Lisaftoclax

Ascentage Pharma Announces New Indication of Olverembatinib Included into China 2024 National Reimbursement Drug List

Ascentage Pharma Appoints Marina S. Bozilenko and Debra Yu as Independent Non-Executive Directors

Ascentage Pharma Received CDE Clearance for Registrational Phase III Studies of APG-2449 for Treatment of Patients with NSCLC

First half 2024 earnings released: EPS: CN¥0.56 (vs CN¥1.47 loss in 1H 2023)

Ascentage Pharma Group International's (HKG:6855) Shares Climb 26% But Its Business Is Yet to Catch Up

Consensus revenue estimates increase by 40%

Forecast to breakeven in 2026

Here's Why Ascentage Pharma Group International (HKG:6855) Can Afford Some Debt

First half 2024 earnings released: EPS: CN¥0.56 (vs CN¥1.47 loss in 1H 2023)

New major risk - Revenue and earnings growth

Ascentage Pharma Clears to Initiate A Registrational Phase III Study of Lisaftoclax, by the Center for Drug Evaluation of China National Medical Products Administration

Ascentage Pharma Group International to Report First Half, 2024 Results on Aug 22, 2024

New minor risk - Shareholder dilution

Ascentage Pharma Group International's (HKG:6855) Shares Climb 29% But Its Business Is Yet to Catch Up

Ascentage Pharma Announces Updated Results from Three Studies of Olverembatinib (HQP1351)

New minor risk - Share price stability

Ascentage Pharma Group International Announces Board and Committee Changes

Ascentage Pharma Releases Updated Clinical Data of olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3%

Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates in 2024 American Society of Clinical Oncology Annual Meeting

Here's Why Ascentage Pharma Group International's (HKG:6855) CEO May Not Expect A Pay Rise This Year

Consensus EPS estimates fall by 15%

Why We're Not Concerned Yet About Ascentage Pharma Group International's (HKG:6855) 30% Share Price Plunge

Ascentage Pharma Group International, Annual General Meeting, May 10, 2024

Full year 2023 earnings released: CN¥3.28 loss per share (vs CN¥3.35 loss in FY 2022)

Ascentage Pharma Group International to Report Fiscal Year 2023 Results on Mar 27, 2024

Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting

Are Investors Undervaluing Ascentage Pharma Group International (HKG:6855) By 40%?

Ascentage Pharma Receives Clearance from the US Food and Drug Administration to Initiate Global Registrational Phase III Trial of Olverembatinib (HQP1351) in Patients with Chronic-Phase Chronic Myeloid Leukemia

Ascentage Pharma Announces Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia (CML) Management from the National Comprehensive Cancer Network (NCCN)

There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price

Ascentage Pharma Group International Presents Preliminary Results from A Phase II Study of Novel Drug Candidate, Olverembatinib

Ascentage Pharma Group International Releases the First Dataset of BCL-2 Inhibitor Lisaftoclax in Patients with R/R Mm, Demonstrating Encouraging ORR and VGPR

Ascentage Pharma Announces the Launch of Olverembatinib in Newly Approved Indication and the Dispatch of First Batch for the New Indication

China National Medical Products Administration Approves Olverembatinib for Treatment of Cml-Cp Patients

Ascentage Pharma Group International to Present Results from Multiple Clinical Studies of olverembatinib and APG-2575 at the 2023 American Society of Hematology(ASH) Annual Meeting, two of which have been Selected for Oral Reports

Ascentage Pharma Group International (HKG:6855) Is Making Moderate Use Of Debt

Ascentage Pharma Releases Latest Data of Pelcitoclax (Apg-1252) Combined with Osimertinib Demonstrates Potential as A New Treatment Option for Tp53-And Egfr-Mutant Nsclc

Ascentage Pharma Announces First Patient Dosed in the Registrational Phase III Study of Olverembatinib in Treatment-Naïve Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia

Ascentage Pharma Announces Global Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Treatment Naïve Patients with CLL/SLL Approved by the China CDE

Consensus revenue estimates fall by 12%

Some Analysts Just Cut Their Ascentage Pharma Group International (HKG:6855) Estimates

First half 2023 earnings released: CN¥1.47 loss per share (vs CN¥1.54 loss in 1H 2022)

There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price

Ascentage Pharma Announces Clearance for Global Registrational Phase III Trial

Ascentage Pharma Group International to Report First Half, 2023 Results on Aug 21, 2023

Ascentage Pharma Group International Receives Clearance from the U.S. Food and Drug Administration to Initiate A Phase 3 Registrational Trial of Lisaftoclax

Ascentage Pharma Group International Announces CDE's Approval for the Phase III Pivotal Study in China of Olverembatinib for the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ All)

Ascentage Pharma Group International (HKG:6855) Is Carrying A Fair Bit Of Debt

Ascentage Pharma Group International Releases Updated Data Showing APG-2449's Potential as a New Treatment for Drug-Resistant NSCLC

Ascentage Pharma Group International Recommends Breakthrough Therapy Designation in China for the Treatment of Sdh-Deficient GIST

Ascentage Pharma Group International Presents Results from Four Studies at 2023 American Society of Clinical Oncology Annual Meeting

Consensus revenue estimates decrease by 22%, EPS upgraded

Full year 2022 earnings: EPS and revenues miss analyst expectations

Ascentage Pharma Group International has completed a Follow-on Equity Offering in the amount of HKD 550.125 million.

Ascentage Pharma Group International's Third-Generation BCR-ABL Inhibitor Olverembatinib Included into the 2022 National Reimbursement Drug List

Ascentage Pharma Group International Releases Preliminary Results from a Global Phase II Study of Lisaftoclax

Ascentage Pharma Delivers Oral Report on the First Dataset from the US Study of Olverembatinib (HQP1351) with Promising Efficacy Observed in Patients Who Failed Prior Treatment with Ponatinib

Ascentage Pharma Group International (HKG:6855) Has Debt But No Earnings; Should You Worry?

Ascentage Pharma's Global Industrial Base Obtains Drug Production Enterprise License

Ascentage Pharma Group International Announces IND Approval in China for Phase I Study of APG-5918 in Patients with Advanced Solid Tumors or Hematologic Malignancies

Ascentage Pharma Group International Announces Released Results from A Phase I Study of the Investigational Inhibitor of Apoptosis Protein (Iap) Antagonist Apg-1387 in Chinese Patients with Chronic Hepatitis B

Ascentage Pharma Releases Phase I Results of Iap Antagonist Apg-1387 in an Oral Report Showing Potential for Functionally Curing Chb

Co-Founder recently bought HK$159k worth of stock

Ascentage Pharma to Present Data of Olverembatinib (HQP1351) in Three Oral Reports, Including the First Dataset from the First US Study, At the ASH Annual Meeting

Ascentage Pharma to Announce Results from First-in-Human Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting

Ascentage Pharma Announces Phase I/Ii Data of Olverembatinib (Hqp1351) Published in the Journal of Hematology & Oncology, Further Validating the Drug's Best-In-Class Potential

Is Ascentage Pharma Group International (HKG:6855) A Risky Investment?